A carregar...
Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria
INTRODUCTION: Due to perceived risk of anaphylaxis, home treatment with omalizumab has been limited. Within the UK, most centres administer omalizumab in a hospital setting. However, the reported prevalence of anaphylaxis is low and in December 2018 home treatment became licensed. A home treatment p...
Na minha lista:
| Publicado no: | Eur J Hosp Pharm |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7856134/ https://ncbi.nlm.nih.gov/pubmed/33097621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2019-001914 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|